ヤギ乳または牛乳ベースの乳児用ミルクを摂取した乳児における胃腸症状と耐容性 (MESK-2)
健康な正期産児におけるヤギ乳ベースの乳児用調製粉乳の胃腸症状および耐容性への影響:二重盲検ランダム化比較試験
This randomized controlled double-blind study will compare the effect of a commercially available goat milk formula to a cow's milk formula on gastrointestinal symptoms and tolerance, and infections in infants.
調査の概要
状態
研究の種類
入学 (推定)
段階
- 適用できない
連絡先と場所
研究連絡先
- 名前:Jildou Visser, BSc
- 電話番号:+31885015283
- メール:clinicaltrials@ausnutria.nl
研究場所
-
-
-
Riyadh、サウジアラビア
- 募集
- King Faissal Specialist Hospital & Research Centre
-
コンタクト:
- Abdullah Aldowaish, Dr.
- 電話番号:0555878540
- メール:dowaish@kfshrc.edu.sa
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Age between 14 days and 90 days.
- Healthy singleton term infants born between 37 weeks and 42 weeks of gestation.
- Infants who have received CMF for at least 7 consecutive days.
- Exclusive formula feeding.
- Cow's Milk-related Symptoms Score (CoMiSS®) value at baseline of ≥6 and <10.
- Parents' or caregivers, aged ≥18 years, willing to give informed consent and adhere to study protocol
Exclusion Criteria:
- Exclusively or partially feeding with human milk
- Introduced to solid food, supplementary feeding, use of pre- and/or probiotics as a supplement
- Congenital or recurrent chronic conditions and/or malabsorption that could interfere with study parameters.
- Diagnosed cow's milk allergy (CMA) or suspected to have CMA, soy allergy, fish allergy, egg allergy and/or lactose intolerance.
- Receiving medication (on own initiative or prescription) with regard to FGID (i.e. reflux medication)
- Sibling already participating in this study
- Participation in another clinical trial
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:4倍
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Intervention group
Goat milk-based infant formula |
Study product is administered on demand until the age of 6 months. |
|
アクティブコンパレータ:Control group
Cow's milk-based infant formula |
Study product is administered on demand until the age of 6 months. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Gastrointestinal symptoms as determined by CoMiSS
時間枠:Difference between groups at Day 14 of the intervention
|
The CoMiSS® is a simple, fast, and easy-to-use awareness tool for cow's milk-related symptoms and may be used in clinical trials to evaluate and quantify the severity of symptoms during a feeding trial. The CoMiSS scores symptoms in five different domains: Crying, Regurgitation, Stools, Skin and Respiratory. The CoMiSS score ranges from 0 to 33 with score 0 as best score (no symptoms) and 33 as worst score (severe symptoms). |
Difference between groups at Day 14 of the intervention
|
|
Gastrointestinal tolerance as determined by IGSQ
時間枠:Difference between groups at the end of the intervention at 24 weeks
|
The IGSQ is a 13-item self-report instrument that has been used in clinical trials to assess infants' GI-related signs and symptoms observed by their parents over the previous week in 5 domains: stooling, regurgitation/vomiting, flatulence, crying, and fussiness. The IGSQ has a possible range of 13 to 65, where higher values indicate greater GI distress and values ≤ 23 indicate no digestive distress. |
Difference between groups at the end of the intervention at 24 weeks
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Gastrointestinal symptoms throughout the study as determined by CoMiSS
時間枠:From enrollment to the end of the intervention at 24 weeks
|
The CoMiSS® is a simple, fast, and easy-to-use awareness tool for cow's milk-related symptoms and may be used in clinical trials to evaluate and quantify the severity of symptoms during a feeding trial. The CoMiSS scores symptoms in five different domains: Crying, Regurgitation, Stools, Skin and Respiratory. The CoMiSS score ranges from 0 to 33 with score 0 as best score (no symptoms) and 33 as worst score (severe symptoms). |
From enrollment to the end of the intervention at 24 weeks
|
|
Gastrointestinal tolerance throughout the study as determined by IGSQ
時間枠:From enrollment to the end of the intervention at 24 weeks
|
The IGSQ is a 13-item self-report instrument that has been used in clinical trials to assess infants' GI-related signs and symptoms observed by their parents over the previous week in 5 domains: stooling, regurgitation/vomiting, flatulence, crying, and fussiness. The IGSQ has a possible range of 13 to 65, where higher values indicate greater GI distress and values ≤ 23 indicate no digestive distress. |
From enrollment to the end of the intervention at 24 weeks
|
|
Occurrence, duration and severity of gastrointestinal infections as determined by Vesikari
時間枠:From enrollment to the end of the intervention at 24 weeks
|
The Vesikari Clinical Severity Scoring System includes a e-diary card completed by parents, to identify rotavirus gastroenteritis episodes. The Vesikari Clinical Severity Scoring System Parameters score ranges from 0 to 20 with score <7 as mild symptoms and score 10 to 20 as severe symptoms. |
From enrollment to the end of the intervention at 24 weeks
|
|
Occurrence, duration and severity of respiratory infections as determined by CARIFS
時間枠:From enrollment to the end of the intervention at 24 weeks
|
Canadian Acute Respiratory Illness and Flu Scale is a validated parental questionnaire, to measure the disease severity of children with acute respiratory illness (ARI) including influenza. CARIFS consists of 18 items covering three domains; symptoms (e.g., cough); function (e.g., play), and parental impact (e.g., clinginess). Each item is scored 0 to 3, with higher scores indicating greater severity of illness. The full scale ranges from 0 to 58. For children older than 5 years the full scale is used; for children younger than 5 years, 3 items (headache, sore throat, and muscle aches) are not used for assessment. |
From enrollment to the end of the intervention at 24 weeks
|
|
Occurrence, duration and severity of ear infections as determined by AOM-SOS V5
時間枠:From enrollment to the end of the intervention at 24 weeks
|
The Acute Otitis Media Symptom Severity scale (AOM-SOS) Version 5.0 is psychometric scale used to measure the severity of symptoms in children with acute otitis media and has been validated for parent-reported use. A 6-point Likert scale ranging from 'No' to 'An extreme amount' is used to rate the presence of 5 symptoms related to acute otitis media over the preceding 24 hours. The AOM-SOS Version 5.0 total score is obtained by summing the scores on these 5 equally-weighted questions. |
From enrollment to the end of the intervention at 24 weeks
|
|
Quality of life as determined by PedsQL
時間枠:From enrollment to the end of the intervention at 24 weeks
|
The Pediatric Quality of Life Inventory (PedsQL™) Infant Scales™ is a specific module of the PedsQL™. The objective of this validated questionnaire is to measure generic health-related quality of life in infants. Applicable for infants with acute and chronic health conditions and healthy infants. The questionnaire is composed of 36 items comprising 5 dimensions: physical functioning, physical symptoms, emotional functioning, social functioning and cognitive functioning. Higher scores means better HRQOL and fewer problems or symptoms. A 5-point Likert scale from is applied: 0 (Never) to 4 (Almost always). Scores are transformed on a scale from 0 to 100. |
From enrollment to the end of the intervention at 24 weeks
|
|
Quality of life as determined by WHOQoL-BREF
時間枠:From enrollment to the end of the intervention at 24 weeks
|
The World Health Organization Quality of Life Questionnaire BREF (WHOQoL-BREF) is the shortened version of the WHOQoL-100. The WHOQoL-BREF measures quality of life within the context of an individual's culture, value systems, personal goals, standards of concerns. The measuring instrument consists of 26 items. The raw scoreis transformed to a 0-100 scale, where higher scores indicate higher perceived quality of life. |
From enrollment to the end of the intervention at 24 weeks
|
|
Weight
時間枠:From enrollment to the end of the intervention at 24 weeks
|
Weight will be measured in kilograms. |
From enrollment to the end of the intervention at 24 weeks
|
|
Height
時間枠:From enrollment to the end of the intervention at 24 weeks
|
Height will be measured in centimeters. |
From enrollment to the end of the intervention at 24 weeks
|
|
Head circumference
時間枠:From enrollment to the end of the intervention at 24 weeks
|
Head circumference will be measured in centimeters. |
From enrollment to the end of the intervention at 24 weeks
|
|
WHO z-scores
時間枠:From enrollment to the end of the intervention at 24 weeks
|
Subject's weight, length and head circumference will be used to calculate the WHO z-scores for weight-for-age, length-for-age, head circumference-for-age, weight-for-length. |
From enrollment to the end of the intervention at 24 weeks
|
|
Fecal parameters
時間枠:Baseline, Day 14, Day 28, Week 12 and Week 24
|
The major fecal bacterial groups are defined using 16S RNA sequencing. Further fecal parameters (e.g. pH, SCFA, sIgA, A1AT) are determined with standard laboratory techniques. |
Baseline, Day 14, Day 28, Week 12 and Week 24
|
|
Sleep and Crying episodes
時間枠:Baseline, Day 14, Day 28, Week 12 and Week 24
|
Sleep and crying episodes and duration are recorded for 24 hours prior to the visits in diaries. |
Baseline, Day 14, Day 28, Week 12 and Week 24
|
|
Stool frequency & consistenty
時間枠:Baseline, Day 14, Day 28, Week 12 and Week 24
|
Stool frequency and consistency are recorded for 24 hours prior to visits in diaries. |
Baseline, Day 14, Day 28, Week 12 and Week 24
|
協力者と研究者
スポンサー
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。